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ObituaryHerman Eisen (1918–2014)Herman Eisen died unexpectedly on
November 2 after spending the day
working on a manuscript on the time
evolution of the heterogeneity of antibody
responses during affinity maturation.
Herman, as he was known to all of us in
the field, was 96, the last of the great
immunochemists whose collective work
established the rules governing the basis
for immunological specificity. He had an
extraordinary career with a continuous
record of important contributions that
extended for more than six decades—
from the 1940s, before the structure of
antibodies was known, to the present,
now dominated by the puzzling and
fascinating questions focused on T cell
recognition of peptide-MHC complexes.
Herman started his career at New York
University after obtaining a medical de-
gree in 1943. He was so impressed by
the classical monograph of Karl Land-
steiner on The Specificity of Serological
Reactions that he decided to focus his
efforts on immunochemistry and study
antibodies. A major interest at this time
was on the development of antibody
responses and the specificities of the
antibody molecules that emerged. Immu-
nochemistry was an extremely active
field with a major focus on examining the
nature of antibody- antigen reactions by
precipitation, hemagglutination, or com-
plement fixation, which were complex
assays. When Herman entered the field
in the late 1940s, nothing much was
known of the structure of immunoglobu-
lins. This was before Rodney Porter
and Gerry Edelman’s classical studies
that defined the two-chain structure of
immunoglobulins. Herman decided to
study antibody reactivity to the hapten
benzene arsonate, rather than more com-
plex protein antigens, which often con-
founded interpretation of the experimental
findings. Using the technique of equilib-
rium dialysis, Herman and Fred Karush
showed, for the first time, that antibody
molecules had two binding sites for anti-
gen. This was amajor finding, and its pub-
lication in JACS in 1949 marked the first
of Herman’s many high impact studies
during a long and productive career.
Herman’s work subsequently advan-
ced to the in-depth analysis of contactsensitivity to dinitrofluorobenzene com-
pounds. We now know that this skin
reactivity is a T cell-dependent delayed
hypersensitivity. These studies brought
Herman to the attention of Barry Wood
and Carl Moore, who were sequential
heads of the Department of Medicine
at Washington University in St. Louis.
Both were visionary physicians, keen on
establishing a strong research base in
a medical department. Herman was
recruited to the Dermatology Division
and moved to St. Louis with his growing
family in 1955. As Herman recently related
to Sondra Schlesinger, who conducted
extensive interviews with him, ‘‘I knew
nothing about dermatology. I knew
enough however to keep my mouth
shut.’’ In fact, upon joining the Washing-
ton University faculty, he spent most
of his time in his research laboratory.
Eventually Herman transferred to the
Department of Microbiology and Immu-
nology where he became chair in 1961.
At Washington University, he continued
to examine the reactions to hapten-
protein conjugates, eventually taking his
studies to the cellular level. This work
focused on 2-4 dinitrophenyl (DNP) conju-
gated to immunogenic carrier proteins.Immunity 41, DThe studies led to a milestone observa-
tion—one of the seminal findings on im-
mune responses—that the affinity of the
antibody response increases over time.
It is therefore worthwhile recalling these
experiments. Rabbits were immunized
with DNP-protein conjugates and specific
antibodies were analyzed after various
time intervals. Herman was able to
precisely measure antibody affinity for
antigen using fluorescence quenching
approaches and observed that the
affinity of serum antibodies to the DNP
hapten increased several hundred-fold
over time, a major study done with Greg-
ory Siskind. Later when Lisa Steiner and
Herman isolated lymph node cells and
determined antibody affinity, they docu-
mented that the time dependent increase
in antibody affinity occurred at the cellular
level. In these early experiments, Her-
man’s laboratory also noted the hetero-
geneity in affinities of antibodies, and an
in-depth study of this heterogeneity was
the subject of his last study.
These experiments were the first to
demonstrate the process of affinity matu-
ration. Affinity maturation was compatible
with the clonal selection theories that
were developed at about this time. At
the same time, these experiments argued
strongly against the alternative template
theory that antibodies acquired their
specificity by folding around antigen
molecules. Affinity maturation was later
explained at the molecular level when
the genetic basis of antibody responses
were uncovered, somatic mutations of
the genes encoding the variable seg-
ments of the antibody molecules became
known, and the germinal center reactions
were elucidated. In brief, the progressive
increase in intrinsic affinity over time is
due to repeated rounds of Darwinian
selection of B cells whose receptors
bind more strongly to antigen, and results
in antibodies that are increasingly more
potent against an invading pathogen.
This theory thus linked the ‘‘fitness’’ of a
B cell to the affinity of the antibody it pro-
duces for antigen. This concept underlies
the development of vaccines that protect
us against a variety of diseases. Affinity
maturation is also mimicked in countless
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Interested in examining the process at
a single cell level, Herman went on to
examine myeloma proteins thinking that
perhaps he would be able to find a homo-
geneous antibody molecule. This even-
tually led him to examine the myeloma
tumors developed by Michael Potter at
the National Institutes of Health, where
he found some, like MOPC-315, that
produced antibody that bound DNP. The
approach of analyzing myeloma proteins
as a monoclonal source of antibodies
preceded the discovery of hybridomas
by Kohler and Milstein by about 10 years,
and provided a raison d’etre for mono-
clonal antibodies that could be generated
against virtually any antigen. Herman’s
studies of these myeloma cells revealed
the polyspecificity of some antibodies,
an issue that captured his interest based
on his broad knowledge of antibody spec-
ificities and affinities.
Herman left St. Louis in 1973 to become
a founding member of the Cancer Center
at theMassachusetts Institute of Technol-
ogy (MIT). Salvador Luria recruited him
to anchor efforts in cancer immunology.
At this time, immunology was changing
dramatically. Now the field not only had
antibodies and B cells to deal with but
also T cells and with them a new way of
antigen recognition. Unlike B cells or their
antibody products, T cells did not recog-
nize soluble antigens, but instead peptide
fragments that were associated with self
MHC molecules. For an immunochemist
like Herman, accustomed to precise
measurement of immunological reactiv-
ities of antibodies in free solution, this
was a new world. However, it was one
which he immediately understood and870 Immunity 41, December 18, 2014 ª2014rapidly became involved in. He had to
adapt to fully understand this new im-
mune complexity—and so he did—and
proceeded to make major contributions
to our understanding of the T cell system.
One of his most significant contributions
to T cell biology came from the analysis
of an isolated CD8 T cell clone, called
2C, derived in his laboratory. 2C was
unique because it recognized an alloge-
neic class I MHC molecule, as well as a
syngeneic MHC molecule. Examining 2C
and its natural ligands provided Herman
with insights into the plasticity of the
recognition of peptide-MHC complexes.
His group also reported that activated
CD8+ T cells could kill a target cell bearing
a single peptide-MHC complex! In toto,
his findings underscored the importance
of the CD8+ T cell subset to immunity to
viruses, cancer, and transplantation reac-
tions. The availability of 2C also allowed
others to examine the 2C clone in other
contexts, fostering precise understanding
of negative and positive selection of
T cells and becoming the first T cell recep-
tor-pMHC complex to be crystallized.
In 1989, Herman retired—the last gen-
eration of faculty members who had to
retire at age 70—but only in the formal
sense. For several years, he maintained
an active laboratory that continued to
make important discoveries. After closing
his laboratory around 2005, he continued
to work closely with several MIT col-
leagues on scientific problems. One of
us (A.K.C.) was greatly influenced by
Herman’s thinking in considering the
specificity-degeneracy puzzle in T cell
recognition of antigen and its implications
for human immune responses.
Herman guided the field in many ways,
not only through his scientific findings butElsevier Inc.also through prominent reviews and
editorials. His deep knowledge of the
literature in immunology extending back
to the 1930s was an unparalleled reposi-
tory of knowledge that many younger
colleagues and students benefited from
until the last day of his life. He wrote the
immunology chapter in Microbiology, the
textbook edited by Bernard Davis that
became for many years the standard
teaching textbook for microbiology and
immunology students.
Herman was also an extraordinarily
generous colleague whose integrity was
respected by all. The term ‘‘gentleman-
scholar’’ is often used loosely—in Her-
man’s case it was an apt description of
the scientist and the man.
Herman received many honors through
his career; among them were his election
to the National Academy of Science,
the Institute of Medicine of the National
Academies, and the American Academy
of Arts and Science. He also received
the Lifetime Achievement Award of the
American Association of Immunologists
in 1997 and served as the President of
this body in 1968.
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